ATE458496T1 - Hiv-vakzine und anwendungsverfahren - Google Patents

Hiv-vakzine und anwendungsverfahren

Info

Publication number: ATE458496T1
Authority: AT; Austria
Prior art keywords: methods; application; hiv vaccines; pharmaceutical compositions; hiv
Prior art date: 2002-01-14

Application number

AT03729676T

Other languages

English (en)

Inventor

Michael Vajdy

Indresh Srivastava

Susan Barnett

Derek O'hagan

Original Assignee

Novartis Vaccines & Diagnostic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-14

Filing date

2003-01-14

Publication date

2010-03-15

2003-01-14 Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ATE458496T1 publication Critical patent/ATE458496T1/de

Links

229960005486 vaccine Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 abstract 2
208000031886 HIV Infections Diseases 0.000 abstract 1
208000037357 HIV infectious disease Diseases 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT03729676T 2002-01-14 2003-01-14 Hiv-vakzine und anwendungsverfahren ATE458496T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34869502P	2002-01-14	2002-01-14
PCT/US2003/001261 WO2003059385A2 (en)	2002-01-14	2003-01-14	Hiv vaccine and method of use

Publications (1)

Publication Number	Publication Date
ATE458496T1 true ATE458496T1 (de)	2010-03-15

Family

ID=23369136

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03729676T ATE458496T1 (de)	2002-01-14	2003-01-14	Hiv-vakzine und anwendungsverfahren

Country Status (8)

Country	Link
US (3)	US20050175631A1 (de)
EP (1)	EP1471936B1 (de)
AT (1)	ATE458496T1 (de)
CA (1)	CA2472579A1 (de)
DE (1)	DE60331412D1 (de)
DK (1)	DK1471936T3 (de)
ES (1)	ES2339762T3 (de)
WO (1)	WO2003059385A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002098368A2 (en) *	2001-06-07	2002-12-12	Wyeth Holdings Corporation	Mutant forms of cholera holotoxin as an adjuvant
US7332174B2 (en)	2001-06-07	2008-02-19	Wyeth Holdings Corporation	Mutant forms of cholera holotoxin as an adjuvant
NZ536859A (en) *	2002-05-14	2007-11-30	Chiron Srl	Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) *	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
WO2005027840A2 (en) *	2003-09-15	2005-03-31	Chiron Corporation	Combination approaches for generating immune responses
EP1945247A1 (de) *	2005-10-18	2008-07-23	Novartis Vaccines and Diagnostics, Inc.	Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
EP2019686B1 (de)	2006-03-31	2012-07-11	Novartis AG	Kombinierte mukosale und parenterale immunisierung gegen hiv
JP5775451B2 (ja)	2008-06-19	2015-09-09	バリエーションバイオテクノロジーズインコーポレイティド	インフルエンザを処置するための組成物および方法
MX2012000372A (es)	2009-07-06	2012-02-28	Variation Biotechnologies Inc	Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en)	2009-07-06	2018-03-06	Variation Biotechnologies, Inc.	Methods for preparing vesicles and formulations produced therefrom
CN107261129A (zh)	2010-05-03	2017-10-20	财团法人生物技术开发中心	用作疫苗的多糖与去毒大肠杆菌(e. coli)不耐热肠毒素(lt)的偶联
CA2840079C (en)	2010-07-06	2018-07-03	Variation Biotechnologies Inc.	Compositions and methods for treating influenza
US10736844B2 (en)	2011-01-13	2020-08-11	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
CA2894442C (en)	2012-01-12	2020-01-21	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
EP4008354A1 (de)	2012-01-27	2022-06-08	Variation Biotechnologies Inc.	Verfahren und zusammensetzungen für therapeutika
CA2959804A1 (en) *	2014-10-08	2016-04-14	Avioq, Inc.	Methods for simultaneous determination of serological profile and estimation of duration post hiv infection
CA3004924A1 (en)	2015-11-10	2017-05-18	Ohio State Innovation Foundation	Methods and compositions related to accelerated humoral affinity
WO2019035972A1 (en) *	2017-08-16	2019-02-21	Georgia State University Research Foundation, Inc.	SEQUENTIAL IMMUNIZATIONS WITH HIV-1 ENV VIRUS TYPE PARTICLES
EP4483898A1 (de) *	2023-06-28	2025-01-01	Advagene Biopharma Co., Ltd.	Intranasale impfstoffzusammensetzung und verfahren zur verstärkung damit

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL89567A0 (en) *	1988-03-28	1989-09-10	Univ Leland Stanford Junior	Mutated hiv envelope protein
US5614612A (en) *	1990-03-09	1997-03-25	Haigwood; Nancy L.	Purified gp120 compositions retaining natural conformation
WO1994028929A1 (en) *	1993-06-07	1994-12-22	Genentech, Inc.	Hiv envelope polypeptides
US6818222B1 (en) *	1997-03-21	2004-11-16	Chiron Corporation	Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
PT1042001E (pt) *	1997-12-16	2002-09-30	Chiron Corp	Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
DE60039715D1 (de) *	1999-11-19	2008-09-11	Csl Ltd	Hcv-impfstoff zusammensetzungen

2003
- 2003-01-14 ES ES03729676T patent/ES2339762T3/es not_active Expired - Lifetime
- 2003-01-14 DK DK03729676.1T patent/DK1471936T3/da active
- 2003-01-14 WO PCT/US2003/001261 patent/WO2003059385A2/en not_active Ceased
- 2003-01-14 AT AT03729676T patent/ATE458496T1/de active
- 2003-01-14 EP EP03729676A patent/EP1471936B1/de not_active Expired - Lifetime
- 2003-01-14 DE DE60331412T patent/DE60331412D1/de not_active Expired - Lifetime
- 2003-01-14 CA CA002472579A patent/CA2472579A1/en not_active Abandoned
- 2003-01-14 US US10/501,606 patent/US20050175631A1/en not_active Abandoned
2008
- 2008-11-28 US US12/324,933 patent/US20090081254A1/en not_active Abandoned
2010
- 2010-11-08 US US12/941,176 patent/US20110045017A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2003059385A3 (en)	2003-08-21
DE60331412D1 (de)	2010-04-08
WO2003059385A2 (en)	2003-07-24
US20090081254A1 (en)	2009-03-26
EP1471936A2 (de)	2004-11-03
US20050175631A1 (en)	2005-08-11
US20110045017A1 (en)	2011-02-24
CA2472579A1 (en)	2003-07-24
EP1471936B1 (de)	2010-02-24
EP1471936A4 (de)	2006-10-25
DK1471936T3 (da)	2010-04-26
ES2339762T3 (es)	2010-05-25

Legal Events

Date

Code

Title

Description

2010-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1471936

Country of ref document: EP

Publication	Publication Date	Title
DE60331412D1 (de)	2010-04-08	Hiv-vakzine und anwendungsverfahren
ATE426412T1 (de)	2009-04-15	Adjuvante influenza-vakzine
IL202978A0 (en)	2011-08-01	West nile virus vaccine
NO20015073L (no)	2001-11-22	Vaksiner
WO2005116270A3 (en)	2007-12-21	Influenza virus vaccine composition and method of use
MX2008013993A (es)	2009-05-11	Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
WO2009072767A3 (en)	2009-07-23	A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
CY1118521T1 (el)	2017-07-12	Συνθεση εμβολιου και μεθοδος χρησης αυτου
HUP0301180A2 (hu)	2004-03-01	Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
ATE499112T1 (de)	2011-03-15	Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
WO2006068663A3 (en)	2006-11-16	Vaccine compositions for treating coronavirus infection
CY1112572T1 (el)	2016-02-10	Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες
NO20061912L (no)	2006-06-02	Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
DE60012042D1 (de)	2004-08-12	Entepneumovirus und entsprechendes impfstoff
IL182440A0 (en)	2007-07-24	Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
WO2005028496A3 (en)	2005-10-06	Vaccine for treatment and prevention of herpes simplex virus infection
WO2004026260A3 (en)	2004-07-15	Prophylactic and therapeutic hiv aptamers
ATE460943T1 (de)	2010-04-15	Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
ATE420658T1 (de)	2009-01-15	Imidazoquinolinamine als adjuvantien für hiv dna vakzine
ATE471990T1 (de)	2010-07-15	Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
BRPI0414073A (pt)	2006-10-24	método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
MX2007002659A (es)	2007-05-16	Composicion vacunal contra el virus de la hepatitis c.
WO2003032917A3 (en)	2003-10-23	Hookworm vaccine
EA200700017A1 (ru)	2009-06-30	Способ усиления иммунного ответа на вакцину
WO2005097179A3 (fr)	2006-10-19	Antigene tat stabilise et ses applications pour la vaccination anti-vih.